European Commission logo
italiano italiano
CORDIS - Risultati della ricerca dell’UE
CORDIS

Nucleic Acids for Future Gene Editing, Immunotherapy and Epigenetic Sequence Modification

Descrizione del progetto

Terapie a base di acido nucleico: una rete di formazione per la ricerca

Le terapie a base di acido nucleico rappresentano un importante progresso nel trattamento delle malattie dell’uomo, e nuovi approcci nella progettazione degli acidi nucleici sono necessari per migliorare le tecnologie di editing genetico, le immunoterapie antitumorali e la manipolazione epigenetica. Il progetto NATURE-ETN, finanziato dall’UE, creerà una rete di formazione alla ricerca nell’ingegneria di nuovi biomateriali e terapie. L’attuale programma di ricerca comprenderà i principali chimici e biologi in combinazione con partner tecnologici e biotecnologici. La rete si avvarrà delle competenze in chimica degli acidi nucleici, cristallografia del DNA, chimica dei materiali, coltura cellulare e sequenziamento epigenetico per sviluppare un ambiente multidisciplinare per offrire formazione a 15 ricercatori nella fase iniziale. La formazione intersettoriale offerta comprenderà competenze scientifiche e trasferibili, una comprensione dell’industria e seminari di sequenziamento, genomica, gestione aziendale e pianificazione della carriera futura.

Obiettivo

Nucleic acid (NAs) therapies are predicted to yield major advances in the treatment of human disease and new approaches in NA design are required to extend the boundaries of today`s gene editing technologies, cancer immunotherapies, and epigenetic base manipulation tools. Current gene editing technologies involving CRISPR-Cas9, despite their wide applicability, have serious limitations involving off-target or prolonged effects that produce mutations, insertions, and deletions leading to undesired therapeutic outcomes. Questions also remain regarding the development and delivery of NAs for manipulation of T-cells, now seen as the new paradigm in cancer research. NATURE-ETN will meet this challenge by engineering new biomaterials and therapies to extend the boundaries of i.) gene editing technology, ii.) cancer immunotherapy, and iii.) epigenetic base manipulation. Our research programme involves world-leading chemists and biologists in combination with high-tech/biotech SMEs and industry partners. We will use our combined expertise in NA chemistry, DNA crystallography, materials chemistry, cell culture, and epigenetic sequencing to develop an outstanding multi-disciplinary environment were 15 Early Stage Researchers will receive unrivalled research training in the most exciting gene therapy research today. The intersectoral training provided will encompass scientific and transferable skills, an understanding of industry, and features targeted workshops in sequencing and genomics along with quality/business management and future career planning. NATURE-ETN will leverage breakthrough discoveries—some originating from our own laboratories—to provide training excellence to give our fellows a deep skillset in the translation of basic research into high functioning commercial NA biomaterials. NATURE-ETN will develop the next generation of pioneering scientific leaders in Europe where they will grow our commercial need for disruptive technologies in 21st century medicine.

Coordinatore

DUBLIN CITY UNIVERSITY
Contribution nette de l'UE
€ 824 052,96
Indirizzo
Glasnevin
9 Dublin
Irlanda

Mostra sulla mappa

Regione
Ireland Eastern and Midland Dublin
Tipo di attività
Higher or Secondary Education Establishments
Collegamenti
Costo totale
€ 824 052,96

Partecipanti (9)